Search Clinical Trials

To evaluate the safety and efficacy of treatment with omecamtiv mecarbil (OM) on Mortality and Morbidity in patients with Chronic Heart Failure with Reduced Ejection Fraction

Primary Investigator: Michell Saltzberg, MD
Subinvestigators:  Nicole Lohr, MD, PhD
 

To determine if market released Cardiac Resynchronization Therapy (CRT) devices which contain the AdaptivCRT(aCRT) algorithm have a superior outcome compared to standard CRT devices in patients with normal AV conduction and Left Bundle Branch Block.

Primary Investigator: Marcie Berger, MD
Subinvestigators: Jason Rubenstein, MD, James Oujiri, MD, James Roth, MD, Nicole Lohr, MD, PhD

Status: Currently enrolling

The purpose of this phase I trial is to study the effects of vonapanitase administered following angioplasty of distal popliteal, tibial or peroneal artery in patients with peripheral vascular disease blinded and in varied dose amounts

Investigators: Parag J. Patel, MD; Kellie Brown, MD; Brian Lewis, MD; Michael Malinowski, MD; Peter Rossi, MD; Matthew Scheidt, MD; Robert Hieb, MD

Status: Currently enrolling

Determine if the use of imaging-guided endovascular therapy (EVT) is an effective strategy with which to reduce Post-Thrombotic (PTS) disease severity and improve quality of life (QOL) in patients with established disabling iliac-obstructive post-thrombotic syndrome (DIO-PTS).

Primary Investigator: Eric J. Hohenwalter, MD, FSIR

Status: Currently enrolling

To determine whether daily supplementation with the probiotic Lactobacillus plantarum 299v improves the function of blood vessels in patients with coronary artery disease.

Primary Investigator: Michael Widlansky, MD, MPH

Status: Open to enrollment 

The purpose of this study is to evaluate whether the 50cc TAH-t can support patients who are imminent risk of death from biventricular heart failure, are eligible for heart transplantation, and for whom the 70cc TAH-t is not appropriate due to size of the chest cavity.

Primary Investigator: David Joyce, MD
Sub-investigators: Lyle Joyce, MD, PhD; Lucian Durham, MD, PhD; Paul Pearson, MD, PhD; Chris Rokkas, MD

Status: Open to enrollment 
 

The purpose of this study is to assess among patients with an acute myocardial infarction and a hemoglobin concentration less than 10 g/dL, if a liberal transfusion strategy with a threshold of 10 g/dL reduces the rate of the composite outcome of all-cause mortality or recurrent nonfatal acute myocardial infarction through 30 days following randomization compared to a restrictive transfusion strategy with a threshold of 7 to 8 g/dL.

Primary Investigator: Michael Gitter, MD
Subinvestigators: Matthew Karafin, MD; Nicole Lohr, MD, PhD; David S. Marks, MD, MBA

Status: Currently enrolling

The purpose of this study is to improve walking distance in patients with intermittent claudication by using ischemic preconditioning.

Investigators: Kellie Brown, MD; Brian Lewis, MD, Michael Malinowski, MD; Peter Rossi, MD, Matt Durand, MD; Julie Freed, MD; and David Gutterman, MD

Status: Currently enrolling

The purpose of this study is to investigate the safety and effectiveness of the RelayPro Thoracic Stent-Grafts in subjects with traumatic injury of the descending thoracic aorta (DTA).

Investigators: Peter Rossi, MD; Kellie Brown, MD; Robert Hieb, MD, Brian Lewis, MD; Michael Malinowski, MD, Parag Patel, MD, MS; William Lea, MD; William Rilling, MD, Sarah White, MD, MS

Status: Currently Enrolling

The purpose of the study is to get information about why IVC filters are used, how often retrievable filters are removed, and to collect health information from patients who have IVC filters. This study is intended to properly categorize the adverse events (injury or harmful effect) related to IVC filters reported in the medical literature. All the IVC filters used in this study are FDA approved.

The IVC Filter Group Foundation is a joint effort between the Society of Interventional Radiology (SIR) and the Society for Vascular Surgery (SVS).

Investigators: Eric J. Hohenwalter, MD; Kellie R.

The BEST-CLI Trial is a multicenter randomized trial of best endovascular (EVT) or best open surgical (OPEN) revascularization in patients with CLI and infrainguinal peripheral arterial occlusive disease (PAOD) who are candidates for both open and endovascular treatment.

Primary Investigators: Parag J. Patel; MD, MS, FSIR
Subinvestigators: Robert A. Hieb, MD, RVT, FSIR; Peter J. Rossi, MD; Kellie Brown, MD; Brian Lewis, MD; Michael Malinowski, MD

Status: Currently enrolling

To demonstrate that the non-invasive blood pressure (NIBP) measurement algorithms on two commercially available devices provide accurate NIBP measurements in accordance with the guidelines provided by the most recent International Organization for Standardization.

Primary Investigator: David S. Marks, MD, MBA 
Subinvestigators: Michael Cinquegrani, MD; Panayotis Fasseas, MD

Status: Open to enrollment 

To develop and to evaluate an alternative method for quantitative determination of donor-specific cell free DNA in plasma of organ transplant recipients as a marker for organ injury — specifically rejection.

Primary Investigator: Nunzio Gaglianello, MD
Subinvestigators: David S. Marks, MD, MBA

Status: Open to enrollment 

The purpose of this research study is to evaluate whether the TAH-t can support patients with life-threatening irreversible biventricular heart failure who are not eligible for transplantation.

Primary Investigator: David Joyce, MD
Subinvestigators: Lyle Joyce, MD, PhD; Lucian Durham, MD, PhD; Paul Pearson, MD, PhD; Chris Rokkas, MD

Status: Open to enrollment